VOAGE 5 10S

About

Dapagliflozin 5mg is an oral medication belonging to the sodium-glucose co-transporter 2 (SGLT2) inhibitor class, primarily used for the treatment of type 2 diabetes mellitus. It works by inhibiting the SGLT2 protein in the kidneys, which is responsible for reabsorbing glucose back into the bloodstream. By blocking this action, dapagliflozin causes the kidneys to excrete more glucose in the urine, thereby lowering blood glucose levels. This mechanism is independent of insulin secretion and sensitivity.

In addition to its glucose-lowering effects, dapagliflozin has demonstrated significant cardiovascular and renal benefits, including a reduction in the risk of cardiovascular death and hospitalization for heart failure, and slowing the progression of kidney disease. It is used as an adjunct to diet and exercise.

Uses

• Treatment of type 2 diabetes mellitus.
• To improve glycemic control in adults.
• To reduce risk of cardiovascular death in certain patients.
• To reduce risk of hospitalization for heart failure.

Directions For Use

Take this medication orally once daily in the morning, with or without food, as directed by your physician.

Benefits

• Effectively lowers blood glucose and HbA1c.
• Reduces risk of cardiovascular events.
• Provides renal protective benefits.
• May lead to modest weight loss.
• Lowers blood pressure.
• Insulin-independent mechanism of action.

Side Effects

• Genital yeast infections
• Urinary tract infections
• Increased urination
• Thirst
• Nausea
• Dizziness
• Hypotension (low blood pressure)
• Back pain
• Ketoacidosis (rare but serious)
• Dehydration
• Flu-like symptoms
• Rash

Safety Measures

• Alcohol - Excessive alcohol consumption can increase the risk of ketoacidosis and may affect blood sugar levels.
• Pregnancy - Not recommended during the second and third trimesters of pregnancy due to potential adverse effects on fetal kidney development.
• Breastfeeding - Not recommended during breastfeeding as it is unknown if dapagliflozin is excreted in human milk.
• Liver - No dose adjustment is typically required for mild to moderate hepatic impairment. Use with caution in severe impairment.
• Kidney - Not recommended for patients with severe renal impairment (eGFR <25 mL/min/1.73m²) due to reduced efficacy.
• Lung - No specific contraindications or significant concerns related to lung conditions.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.